Parkin inhibits iron overload-induced cardiomyocyte ferroptosis by ubiquitinating ACSL4 and modulating PUFA-phospholipids metabolism
- PMID: 40370554
- PMCID: PMC12069115
- DOI: 10.1016/j.apsb.2024.12.027
Parkin inhibits iron overload-induced cardiomyocyte ferroptosis by ubiquitinating ACSL4 and modulating PUFA-phospholipids metabolism
Abstract
Iron overload is strongly associated with heart disease. Ferroptosis is a new form of regulated cell death indicated in cardiac ischemia-reperfusion (I/R) injury. However, the specific molecular mechanism of myocardial injury caused by iron overload in the heart is still unclear, and the involvement of ferroptosis in iron overload-induced myocardial injury is not fully understood. In this study, we observed that ferroptosis participated in developing of iron overload and I/R-induced cardiomyopathy. Mechanistically, we discovered that Parkin inhibited iron overload-induced ferroptosis in cardiomyocytes by promoting the ubiquitination of long-chain acyl-CoA synthetase 4 (ACSL4), a crucial protein involved in ferroptosis-related lipid metabolism pathways. Additionally, we identified p53 as a transcription factor that transcriptionally suppressed Parkin expression in iron-overloaded cardiomyocytes, thereby regulating iron overload-induced ferroptosis. In animal studies, cardiac-specific Parkin knockout mice (Myh6-CreER T2 /Parkin fl/fl ) fed a high-iron diet presented more severe myocardial damage, and the high iron levels exacerbated myocardial I/R injury. However, the ferroptosis inhibitor Fer-1 significantly suppressed iron overload-induced ferroptosis and myocardial I/R injury. Moreover, Parkin effectively protected against impaired mitochondrial function and prevented iron overload-induced mitochondrial lipid peroxidation. These findings unveil a novel regulatory pathway involving p53-Parkin-ACSL4 in heart disease by inhibiting of ferroptosis.
Keywords: ACSL4; Ferroptosis; Heart diseases; I/R; Iron overload; Mitochondrial; Parkin; p53.
© 2025 The Authors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures









Similar articles
-
HJ11 decoction restrains development of myocardial ischemia-reperfusion injury in rats by suppressing ACSL4-mediated ferroptosis.Front Pharmacol. 2022 Nov 22;13:1024292. doi: 10.3389/fphar.2022.1024292. eCollection 2022. Front Pharmacol. 2022. PMID: 36483736 Free PMC article.
-
Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion.Cell Death Differ. 2019 Nov;26(11):2284-2299. doi: 10.1038/s41418-019-0299-4. Epub 2019 Feb 8. Cell Death Differ. 2019. PMID: 30737476 Free PMC article.
-
Deficiency of mitochondrial calcium uniporter abrogates iron overload-induced cardiac dysfunction by reducing ferroptosis.Basic Res Cardiol. 2023 May 25;118(1):21. doi: 10.1007/s00395-023-00990-7. Basic Res Cardiol. 2023. PMID: 37227592 Free PMC article.
-
Inhibition of ACSL4 attenuates ferroptotic damage after pulmonary ischemia-reperfusion.FASEB J. 2020 Dec;34(12):16262-16275. doi: 10.1096/fj.202001758R. Epub 2020 Oct 18. FASEB J. 2020. PMID: 33070393
-
The effects of iron overload on mitochondrial function, mitochondrial dynamics, and ferroptosis in cardiomyocytes.Arch Biochem Biophys. 2020 Feb 15;680:108241. doi: 10.1016/j.abb.2019.108241. Epub 2019 Dec 28. Arch Biochem Biophys. 2020. PMID: 31891670 Review.
References
-
- Fernández Real J.M., López Bermejo A., Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51:2348–2354. - PubMed
-
- Zhang J., Song Y., Li Y., Lin H.B., Fang X. Iron homeostasis in the heart: molecular mechanisms and pharmacological implications. J Mol Cell Cardiol. 2023;174:15–24. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous